Peptide education
Nonapeptide-1
Melanostatine-5
Nonapeptide-1 is a synthetic peptide made of nine amino-acid building blocks. It is used in cosmetic products marketed for the appearance of uneven skin tone. Laboratory work has examined it in pigment-producing cells.
Small randomized studies evaluated combination regimens containing nonapeptide-1. Neither isolated its effect, and one maintenance pilot found no statistically significant difference from sunscreen in reported melasma severity or instrument-measured skin pigmentation.
Overview
Quick answer
A cell experiment and a finished skin-care product answer different questions. Human trials have included nonapeptide-1 in mixtures with other active ingredients, so the peptide's contribution cannot be separated.
Has it been studied in people?
Yes, as one component of combination products in small trials involving people with melasma. Other ingredients and treatments were also used.
Does it treat a pigment disorder on its own?
The cited trials did not isolate the peptide, so they cannot establish its effect as a stand-alone treatment.
What has been studied in cells?
A laboratory study used nonapeptide-1 acetate in human skin cells while examining melanin and signals involved in making it. Alpha-MSH is a signaling molecule, and MC1R is a receptor that responds to that signal.
Evidence
Evidence snapshot
A combination product was compared with sunscreen after initial treatment.
Both groups also received oral tranexamic acid; the topical products differed.
Researchers measured melanin and pigment-related proteins in the laboratory.
Short studies reported adverse events for complete regimens, not the isolated peptide.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Verdict |
|---|---|---|---|
| Nonapeptide-1 alone treats melasma. | The studies used formulations containing several actives, with prior treatment or oral medication also part of the study design. | Pigment-related cell findings do not establish a clinical treatment effect. | The peptide's independent clinical effect was not measured. |
| A combination product is equivalent to hydroquinone. | A small trial found no statistically significant between-group difference in measured outcomes when each topical product was combined with oral tranexamic acid. | A nonsignificant difference in this study does not establish equivalence. |
Bottom line
Main takeaway
Products containing the peptide have been studied, but their results cannot be assigned to the peptide alone.
The other ingredients, sun protection, and concurrent treatments matter when comparing results.
Review the initial treatment, comparator, missing participants, and endpoints alongside each formulation.
Identity
What it is
Nonapeptide-1 is a synthetic peptide used in formulations aimed at the appearance of uneven pigmentation. A laboratory study used its acetate form in experiments with cultured human skin cells.
One maintenance product contained the peptide along with other ingredients and sunscreen. A separate study tested a different multi-ingredient essence.
Research
Research evidence
Two randomized studies tested combinations in people with melasma. Neither compared a formulation with and without nonapeptide-1 as its only difference.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Randomized maintenance pilot | 46 people with melasma enrolled; 31 completed follow-up | Randomized before shared initial treatment, followed by combination product versus sunscreen | Nonapeptide-1, phenyl ethyl resorcinol, aminoethyl phosphinic acid, antioxidants, and sunscreen | The reported severity scores and skin-pigment readings did not differ significantly from the control group. | Small sample, loss to follow-up, prior treatment, and multiple active ingredients. Palsons Derma supported the study; the authors reported independent assessment and analysis. | Limited human evidence for the combination |
| Randomized combination-essence study | 62 women with melasma enrolled; 59 completed | Twelve-week comparison of two topical regimens, both with oral tranexamic acid | An essence containing nonapeptide-1, Cordyceps extract, arbutin, and glabridin versus hydroquinone cream | Both groups improved from baseline; reported between-group differences were not statistically significant. | No peptide-only or matched-vehicle arm; the study did not establish equivalence. | Limited human evidence for the combination regimen |
Use context
Reported use context
These schedules describe the complete study regimens, including other treatments.
Study and label context
Participants were randomized before eight weeks of shared initial treatment. The combination product or sunscreen was then applied twice daily for 16 weeks.
The combination included sunscreen and other actives; the peptide's concentration was not specified.Participants received the assigned regimen for 12 weeks. The paper listed nonapeptide-1 at 3% in the essence.
The paper does not clarify the percentage basis. The essence contained several actives, and both groups also took oral tranexamic acid.Cautions
Safety and unknowns
- In the essence trial, one participant in the combination-product group reported facial itching. The study could not determine which ingredient caused it.
- In the maintenance phase, one participant using the combination reported itching. Other reactions were reported in the sunscreen group and during the earlier shared treatment. The pilot cannot exclude uncommon or delayed effects.
- Long-term safety of the peptide as an isolated topical ingredient remains uncertain.
Product quality
Product identity and quality
A result for one multi-ingredient formulation does not describe the contents or performance of another.
Ingredient list
Other active ingredients may affect both the result and tolerability.
Product strength
Supplier solution percentages and actual peptide content may differ.
Sun protection
The maintenance study used sunscreen in both groups.
Mechanism
How it is proposed to work
Melanocytes make melanin, a pigment that contributes to skin color. A cell study used nonapeptide-1 acetate while examining signals associated with melanin production.
The researchers examined the alpha-MSH and MC1R pathway in cultured human skin cells, including experiments with the peptide alone and alongside tea polyphenols.
Changes in cultured cells do not establish delivery, efficacy, or safety in a finished skin-care product.
Details
Technical details
Sources
References
- 1.
doi:10.5114/ada.2022.115890 PMID:35645678
Human-cell experiments included nonapeptide-1 acetate as a comparator, alone and alongside tea polyphenols.
- 2.
Indian Journal of Dermatology, Venereology and Leprology. A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance
doi:10.25259/IJDVL_976_18 PMID:34379946
The pilot randomized 46 participants before shared initial treatment; 31 completed follow-up. Palsons Derma supported the study, and the authors reported independent assessment and analysis.
- 3.
Journal of Cosmetic Dermatology. Effect of a New Skin-Lightening Cosmetic Containing Cordyceps Extract in the Treatment of Melasma: A Clinical Trial
doi:10.1111/jocd.70329
A randomized study enrolled 62 women; 59 completed. It compared oral tranexamic acid plus a multi-ingredient essence with oral tranexamic acid plus hydroquinone.
- 4.
FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)
A product's intended use affects its US regulatory classification.